Financial Performance - For the six months ended December 31, 2023, the company reported revenue of HKD 18,844,000, an increase of 25.5% compared to HKD 15,025,000 for the same period in 2022[5]. - The gross profit for the six months was HKD 3,121,000, representing a slight increase of 2.7% from HKD 3,039,000 in the previous year[5]. - The company incurred a loss before tax of HKD 2,239,000, compared to a profit of HKD 15,769,000 in the same period last year, indicating a significant decline[5]. - The total comprehensive loss for the period was HKD 3,315,000, compared to a comprehensive income of HKD 13,542,000 in the previous year[7]. - The company reported a basic loss per share of HKD 0.29 for the three months ended December 31, 2023, compared to earnings per share of HKD 6.07 in the same period last year[7]. - The group reported a loss of HKD 2,239,000 for the six months ended December 31, 2023, compared to a profit of HKD 15,769,000 for the same period in 2022, indicating a significant decline in profitability[21]. - The total comprehensive loss for the period was HKD 4,151,000, compared to a total comprehensive income of HKD 13,542,000 for the same period in 2022, indicating a shift of approximately 130.7% in performance[11]. - The company reported a loss attributable to equity holders of HKD 2,876,000 for the six months ended December 31, 2023, compared to a profit of HKD 15,408,000 for the same period in 2022, representing a significant decline[34]. - The company recorded a basic and diluted loss per share of HKD 0.0156 for the six months ended December 31, 2023, compared to earnings per share of HKD 0.0849 for the same period in 2022[34]. Assets and Liabilities - The company's non-current assets amounted to HKD 9,528,000 as of December 31, 2023, an increase from HKD 6,437,000 as of June 30, 2023[8]. - Current assets increased to HKD 36,702,000 from HKD 27,045,000, primarily driven by an increase in inventory and cash[8]. - The company's total liabilities were HKD 228,739,000, up from HKD 213,236,000, reflecting an increase in trade payables[8]. - Total assets as of December 31, 2023, amounted to HKD 46,230,000, an increase from HKD 33,482,000 as of June 30, 2023[19]. - The company’s total liabilities increased slightly, with net liabilities reported at HKD 182,509,000 as of December 31, 2023, compared to HKD 179,754,000 as of June 30, 2023[10]. - The company’s total liabilities increased to HKD 112,959,000 as of December 31, 2023, compared to HKD 107,456,000 as of June 30, 2023, showing an increase of about 5.3%[40]. Cash Flow - The company reported a net cash outflow from operating activities of HKD 1,317,000 for the six months ended December 31, 2023, compared to a net cash inflow of HKD 4,720,000 for the same period in 2022, representing a significant decline in cash generation[13]. - Cash and cash equivalents at the end of the period increased to HKD 8,505,000 from HKD 7,283,000 at the end of the previous year, marking a growth of 16.7%[13]. - The company did not incur any interest payments during the six months ended December 31, 2023, compared to HKD 3,500,000 in interest payments for the same period in 2022[13]. Strategic Focus and Future Outlook - The company has not provided specific guidance for future performance but indicated ongoing efforts in product development and market expansion[6]. - The company is focusing on enhancing its operational efficiency and exploring potential strategic partnerships to drive growth[6]. - The company is focusing on the "Internet+" business and the health product sector, leveraging its supply chain service experience to explore new development opportunities[58]. - The company plans to accelerate its investment in the health industry supply chain services while reallocating resources away from personal protective equipment due to decreased market demand[57]. Share Capital and Convertible Bonds - The company issued convertible bonds with a principal amount of HKD 89,625,000 at an annual interest rate of 10%, with a conversion price adjusted to HKD 0.221 per share[46]. - The total outstanding balance of the convertible bonds at maturity was HKD 105,747,000, which includes the principal and accrued interest[46]. - The company issued a second set of convertible bonds with a principal amount of HKD 50,000,000, maturing on February 20, 2023, at an annual interest rate of 7%[47]. - The initial conversion price for the second set of convertible bonds is HKD 0.29, allowing for the issuance of up to 172,413,793 shares upon full conversion[47]. - The company’s share capital remained unchanged at HKD 57,404,000 as of December 31, 2023, consistent with the previous reporting period[11]. - The company’s share capital was consolidated on August 29, 2023, with every 25 shares of HKD 0.0125 par value consolidated into one share of HKD 0.3125[92]. Corporate Governance - The company has adopted and complied with the applicable code provisions of the GEM Listing Rules, with some deviations noted regarding the separation of the roles of Chairman and CEO[98]. - The company confirmed that all directors adhered to the trading code of conduct during the review period[100]. - The audit committee consists of three independent non-executive directors, including Mr. Liu Fei as the chairman, and has reviewed the unaudited results for the six months ending December 31, 2023[103]. - The company has complied with the GEM Listing Rules regarding the appointment of independent non-executive directors after the recent appointments[101]. Employment and Staff - The company employed 18 staff members as of December 31, 2023, down from 19 as of June 30, 2023[72].
国药科技股份(08156) - 2024 - 中期业绩